Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


03.10.2017

7 Am J Hematol
1 Ann Hematol
1 Ann Oncol
1 Biochem Pharmacol
4 Blood
2 Cancer
2 Cancer Res
1 Eur J Haematol
2 Exp Hematol
1 Gene
1 Int J Hematol
1 J Biol Chem
1 J Immunol
2 J Pediatr Hematol Oncol
1 Leuk Lymphoma
2 Leuk Res
11 Leukemia
2 Oncogene
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. BRECCIA M, Colafigli G, Molica M, Scalzulli E, et al
    Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
    Am J Hematol. 2017 Sep 28. doi: 10.1002/ajh.24916.
    PubMed     Text format    

  2. SHIMONI A, Vago L, Bernardi M, Yerushalmi R, et al
    Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Am J Hematol. 2017;92:1011-1019.
    PubMed     Text format     Abstract available

  3. RASHIDI A, Linden MA, DeFor TE, Warlick E, et al
    History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Am J Hematol. 2017;92:1032-1036.
    PubMed     Text format     Abstract available

  4. SPERR WR, Herndlhofer S, Gleixner K, Girschikofsky M, et al
    Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >/=60 years.
    Am J Hematol. 2017;92:E567-E574.
    PubMed     Text format     Abstract available

  5. HAMPEL PJ, Chaffee KG, King RL, Simonetto D, et al
    Liver Dysfunction in Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings.
    Am J Hematol. 2017 Sep 22. doi: 10.1002/ajh.24915.
    PubMed     Text format     Abstract available

  6. GAKSCH L, Kashofer K, Heitzer E, Quehenberger F, et al
    Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Sep 29. doi: 10.1002/ajh.24922.
    PubMed     Text format     Abstract available

  7. GORIN NC, Labopin M, Pabst T, Remenyi P, et al
    Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
    Am J Hematol. 2017 Sep 11. doi: 10.1002/ajh.24904.
    PubMed     Text format     Abstract available


    Ann Hematol

  8. HOU J, Wang S, Zhang Y, Fan D, et al
    Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Ann Hematol. 2017 Sep 22. doi: 10.1007/s00277-017-3130.
    PubMed     Text format     Abstract available


    Ann Oncol

  9. HEIDRICH K, Thiede C, Schafer-Eckart K, Schmitz N, et al
    Allogeneic Hematopoietic Cell Transplantation in Intermediate Risk Acute Myeloid Leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA Mutations.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    Biochem Pharmacol

  10. STEINHILBER D, Marschalek R
    How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
    Biochem Pharmacol. 2017 Sep 21. pii: S0006-2952(17)30603.
    PubMed     Text format     Abstract available


    Blood

  11. KATAYAMA S, Suzuki M, Yamaoka A, Keleku-Lukwete N, et al
    GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Blood. 2017;130:908-919.
    PubMed     Text format     Abstract available

  12. LIN S, Ptasinska A, Chen X, Shrestha M, et al
    A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Blood. 2017;130:1213-1222.
    PubMed     Text format     Abstract available

  13. MUELLER KT, Maude SL, Porter DL, Frey N, et al
    Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
    Blood. 2017 Sep 21. pii: blood-2017-06-786129. doi: 10.1182/blood-2017-06-786129
    PubMed     Text format     Abstract available

  14. THAKRAL B, Wang SA
    "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
    Blood. 2017;130:1600.
    PubMed     Text format    


    Cancer

  15. FATHI AT, Blonquist TM, Hernandez D, Amrein PC, et al
    Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31038.
    PubMed     Text format     Abstract available

  16. SCHEICH S, Lindner S, Koenig R, Reinheimer C, et al
    Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31045.
    PubMed     Text format     Abstract available


    Cancer Res

  17. HOU P, Wu C, Wang Y, Qi R, et al
    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
    Cancer Res. 2017;77:4402-4413.
    PubMed     Text format     Abstract available

  18. ZHANG H, Means S, Schultz AR, Watanabe-Smith K, et al
    Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.
    Cancer Res. 2017;77:4258-4267.
    PubMed     Text format     Abstract available


    Eur J Haematol

  19. KAYSER S, Feszler M, Krzykalla J, Schick M, et al
    Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients.
    Eur J Haematol. 2017 Sep 22. doi: 10.1111/ejh.12972.
    PubMed     Text format     Abstract available


    Exp Hematol

  20. GREGORY MA, Nemkov T, Reisz JA, Zaberezhnyy V, et al
    Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Exp Hematol. 2017 Sep 22. pii: S0301-472X(17)30776.
    PubMed     Text format     Abstract available

  21. CHAN LN, Muschen M
    B-cell identity as a metabolic barrier against malignant transformation.
    Exp Hematol. 2017;53:1-6.
    PubMed     Text format     Abstract available


    Gene

  22. KAYABASI C, Okcanoglu TB, Yelken BO, Asik A, et al
    Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Gene. 2017 Sep 20. pii: S0378-1119(17)30759-X. doi: 10.1016/j.gene.2017.
    PubMed     Text format     Abstract available


    Int J Hematol

  23. USUI N
    JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2017 Sep 21. doi: 10.1007/s12185-017-2330.
    PubMed     Text format    


    J Biol Chem

  24. BROWN LM, Hanna DT, Khaw SL, Ekert PG, et al
    Dysregulation of BCL-2 family proteins by leukemia fusion genes.
    J Biol Chem. 2017;292:14325-14333.
    PubMed     Text format     Abstract available


    J Immunol

  25. SUN HM, Chen XL, Chen XJ, Liu J, et al
    PALLD Regulates Phagocytosis by Enabling Timely Actin Polymerization and Depolymerization.
    J Immunol. 2017;199:1817-1826.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  26. FELICE MS, Rossi JG, Alonso CN, Rubio P, et al
    Second Neoplasms in Children Following a Treatment for Acute Leukemia and/or Lymphoma: 29 Years of Experience in a Single Institution in Argentina.
    J Pediatr Hematol Oncol. 2017 Sep 22. doi: 10.1097/MPH.0000000000000971.
    PubMed     Text format     Abstract available

  27. KAYILIOGLU H, Kocak U, Kan Karaer D, Percin EF, et al
    Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    J Pediatr Hematol Oncol. 2017;39:458-462.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  28. HOOGEVEEN PG, de Bie M, Noordijk R, Sonneveld E, et al
    Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Sep 28:1-3. doi: 10.1080/10428194.2017.1382699.
    PubMed     Text format    


    Leuk Res

  29. WEBSTER JA, Tibes R, Morris L, Blackford AL, et al
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
    Leuk Res. 2017;61:108-116.
    PubMed     Text format     Abstract available

  30. SAHAI T, Henrichs K, Refaai M, Heal JM, et al
    ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.
    Leuk Res. 2017;62:1-3.
    PubMed     Text format     Abstract available


    Leukemia

  31. EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
    Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
    Leukemia. 2017;31:734-738.
    PubMed     Text format    

  32. RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
    Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
    Leukemia. 2017;31:1603-1610.
    PubMed     Text format     Abstract available

  33. RONCHINI C, Brozzi A, Riva L, Luzi L, et al
    PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
    Leukemia. 2017;31:1975-1986.
    PubMed     Text format     Abstract available

  34. SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
    Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Leukemia. 2017;31:1951-1961.
    PubMed     Text format     Abstract available

  35. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    The clonal origins of leukemic progression of myelodysplasia.
    Leukemia. 2017;31:1928-1935.
    PubMed     Text format     Abstract available

  36. CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
    Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
    Leukemia. 2017;31:1513-1524.
    PubMed     Text format     Abstract available

  37. FUJITA S, Honma D, Adachi N, Araki K, et al
    Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  38. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  39. BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
    NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
    Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  40. RINKE J, Muller JP, Blaess MF, Chase A, et al
    Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Leukemia. 2017;31:1936-1943.
    PubMed     Text format     Abstract available

  41. HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
    Measurable residual disease testing in acute myeloid leukaemia.
    Leukemia. 2017;31:1482-1490.
    PubMed     Text format     Abstract available


    Oncogene

  42. SERIO J, Ropa J, Chen W, Mysliwski M, et al
    The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available

  43. YOUN H, Lee HK, Sohn HR, Park UH, et al
    RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    PLoS One

  44. ISAEVSKA E, Manasievska M, Alessi D, Mosso ML, et al
    Cancer incidence rates and trends among children and adolescents in Piedmont, 1967-2011.
    PLoS One. 2017;12:e0181805.
    PubMed     Text format     Abstract available

  45. FATEHCHAND K, Santhanam R, Shen B, Erickson EL, et al
    Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells.
    PLoS One. 2017;12:e0181729.
    PubMed     Text format     Abstract available

  46. PRABHU KS, Siveen KS, Kuttikrishnan S, Iskandarani A, et al
    Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells.
    PLoS One. 2017;12:e0180895.
    PubMed     Text format     Abstract available

  47. LEE CH, Lin JC, Ho CL, Sun M, et al
    Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
    PLoS One. 2017;12:e0180050.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: